ESTRADIOL | A040197 | BARR LABORATORIES INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Hyman, Phelps & McNamara, P.C. FDA-2026-P-2259 · 7 docket documents Hyman, Phelps & McNamara, P.C., on behalf of a client, filed this suitability petition under Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act requesting that FDA declare Estradiol Tablets in 0.25 mg and 0.75 mg strengths suitable for ANDA submission, based on the reference listed drug | Suitability | 2026-03-04 | Open | Hyman, Phelps & McNamara, P.C. |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.0807
per ea
Lowest NADAC/Unit
$0.0592
per ea
Brand NDCs
0
Generic NDCs
6
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00555088702ESTRADIOL 2 MG TABLET | $0.0807 | EA | Generic | — | 2026-06-17 |
| 00555088704ESTRADIOL 2 MG TABLET | $0.0807 | EA | Generic | — | 2026-06-17 |
| 00555088602ESTRADIOL 1 MG TABLET | $0.0650 | EA | Generic | — | 2026-06-17 |
| 00555088604ESTRADIOL 1 MG TABLET | $0.0650 | EA | Generic | — | 2026-06-17 |
| 60687087665ESTRADIOL 1 MG TABLET | $0.0650 | EA | Generic | — | 2026-06-17 |
| 00555089902ESTRADIOL 0.5 MG TABLET | $0.0592 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.